With just two weeks until the end of the CPD year, the Guild Academy has announced an online course to assist pharmacists in understanding the use of Ellipta devices in COPD and asthma.
The 2014-15 Australian Health Survey estimated that 2.5 million Australians are affected by asthma and a further 600,000 are affected by COPD. Respiratory conditions are among the most commonly managed health problems and pharmacists are well-placed to assist customers in dealing with this health condition.
This new online course will provide pharmacists with the key clinical characteristics of asthma and chronic obstructive pulmonary disease and enable them to recommend both drug and non-drug approaches to managing asthma and COPD.
Anthony Tassone, the President of the Pharmacy Guild of Australia—Victoria says he believes this online course will provide important advice to community pharmacists regarding the pharmacology and role in therapy of fluticasone furoate, umeclidinium and vilanterol in the management of respiratory conditions.
“Asthma and COPD are key health conditions where pharmacists can have a significant impact in establishing a relationship with the patient and working with them on an ongoing basis to treat and manage their condition,” he says.
The online course also includes the key characteristics of the new respiratory drug delivery device and provides pharmacists with counselling tips to assist patients who have been prescribed these medicines.
The completion of this online course will attract 1.5 Group Two CPD Credits following the successful completion of an assessment and is available on the Guild Academy’s myCPD site.
The Guild Pharmacy Academy would like to thank GSK for its support and input of expertise in the development of this course.